التفاصيل البيبلوغرافية
| العنوان: |
Results of Thoracic Endovascular Aortic Repair 6 Years After United States Food and Drug Administration Approval. |
| المؤلفون: |
Shah, Asad A., Barfield, Michael E., Andersen, Nicholas D., Williams, Judson B., Shah, Julie A., Hanna, Jennifer M., McCann, Richard L., Hughes, G. Chad |
| المصدر: |
Annals of Thoracic Surgery; Nov2012, Vol. 94 Issue 5, p1394-1399, 6p |
| مصطلحات موضوعية: |
THORACIC aneurysms, LONGITUDINAL method, DEGENERATION (Pathology), DISEASES, CARDIOPULMONARY system, HEALTH outcome assessment, THERAPEUTICS |
| مصطلحات جغرافية: |
UNITED States |
| الشركة/الكيان: |
UNITED States. Food & Drug Administration |
| مستخلص: |
Background: Since United States Food and Drug Administration approval in 2005, the short-term safety and efficacy of thoracic endovascular aortic repair (TEVAR) have been established. However, longer-term follow-up data remain lacking. The objective of this study is to report 6-year outcomes of TEVAR in clinical practice. Methods: A prospective cohort review was performed of all patients undergoing TEVAR at a single referral institution between March 2005 and May 2011. Rates of reintervention were noted. Overall and aortic-specific survival were determined using Kaplan-Meier methods. Log-rank tests were used to compare survival between groups. Results: During the study interval, 332 TEVAR procedures were performed in 297 patients. Reintervention was required after 12% of procedures at a mean of 8 ± 14 months after initial TEVAR and was higher in the initial tercile of patients (15.0% vs 9.9%). The 6-year freedom from reintervention was 84%. Type I endoleak was the most common cause of reintervention (5%). Six-year overall survival was 54%, and aorta-specific survival was 92%. Long-term survival was significantly lower than that of an age- and sex-matched United States population (p < 0.001). Survival was similar between patients requiring a reintervention vs those not (p = 0.26). Survival was different based on indication for TEVAR (p = 0.007), and patients with degenerative aneurysms had the lowest survival (47% at 6 years). Cardiopulmonary pathologies were the most common cause of death (27 of 93 total deaths). Conclusions: Long-term aortic-related survival after TEVAR is high, and the need for reintervention is infrequent. However, overall long-term survival is low, particularly for patients with degenerative aneurysms, and additional work is needed to identify patients unlikely to derive a survival benefit from TEVAR. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Thoracic Surgery is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
Full Text Finder